Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
Researchers reached this conclusion by analyzing markers of immune activity in women’s genital tracts.
In some non–U.S. nations, health care providers can prescribe medical-grade heroin and supervise patients as they take it.
Researchers believe this genetic mutation protected against the 14th century-bubonic plague.
A recent study of people in British Columbia found, however, that people who inject drugs had lower cure rates.
Both cases involve mothers with an undetectable, or at least very low, viral load transmitting HIV to their babies.
Researchers believe that macrophage cells in the liver that harbor such inert HIV are not a part of the viral reservoir.
Such effects have a downstream impact on the real-world functioning of people with HIV.
Half of all those diagnosed in the World Health Organization European Union already have an advanced stage of HIV disease.
Researchers have found a way of stabilizing a shape-shifting viral protein so as to promote a greater antibody response.
The tablet from the South Korean company Celltrion contains tenofovir disoproxil fumarate and lamivudine.
This finding suggests sex between men and the sharing of drug-sniffing equipment are possible routes of transmission.
A pair of twin girls have been born as a part of his efforts, greatly alarming the worldwide research community.
In a recent trial, Gilead’s regimen was highly successful in a group that included those with and without HIV coinfection.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.